Upping our Game: How Canada's Financial Sector Can Spur Economic Performance
In: C.D. Howe Institute e-Brief 314
14 Ergebnisse
Sortierung:
In: C.D. Howe Institute e-Brief 314
SSRN
In: C.D. Howe Institute Commentary 593
SSRN
In: C.D. Howe Institute Commentary 601
SSRN
In: C.D. Howe Institute e-brief 293 (2019)
SSRN
In: C.D. Howe Institute Commentary 522
SSRN
Working paper
In: C.D. Howe Institute Commentary 581
SSRN
In: C.D. Howe Institute Commentary 565
SSRN
Working paper
In: C.D. Howe Institute Commentary 548
SSRN
Working paper
In: C.D. Howe Institute e-Brief 292, May 2019
SSRN
Working paper
In: C.D. Howe Institute Commentary 545, 2019, ISBN 978-1-989483-05-3
SSRN
Working paper
In: C.D. Howe Institute Commentary 560
SSRN
Working paper
In: C.D. Howe Institute Commentary 512
SSRN
Working paper
In: C.D. Howe Institute Commentary 527
SSRN
Working paper
In: The Canadian journal of economics: the journal of the Canadian Economics Association = Revue canadienne d'économique, Band 56, Heft 1, S. 288-305
ISSN: 1540-5982
AbstractTemporary randomized controlled trials are susceptible to transitory effects that would not result from a permanent treatment. We find a large and statistically significant "deadline effect"—a surge in spending in the final treatment year—in the RAND Health Insurance Experiment, identified by random allocation to three‐ or five‐year enrolment terms. Participants facing lower coinsurance rates show larger spending surges. Partialing out the price–deadline interaction reduces in magnitude estimates of the permanent price elasticity of drug spending (and in some specifications of outpatient and supplies spending). This implies higher optimal coinsurance rates and illustrates the importance of experimental design to identifying parameters of interest in randomized controlled trials.